Refine
Year of publication
Document Type
- Preprint (699)
- Article (587)
- Conference Proceeding (7)
- Book (4)
- Working Paper (4)
- Report (2)
- Part of a Book (1)
- Review (1)
Has Fulltext
- yes (1305)
Is part of the Bibliography
- no (1305)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- COVID-19 (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Depression (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- Multimorbidity (3)
- Treatment (3)
- pp collisions (3)
- Acute myeloid leukemia (2)
- Algorithms (2)
- Artificial intelligence (2)
- Beauty production (2)
- Bone density (2)
- CT (2)
- Charm physics (2)
- Chronic disease (2)
- Clinical decision support systems (2)
- Collectivity (2)
- Computer-assisted diagnosis (2)
- Correlation (2)
- Diffraction (2)
- Elastic scattering (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Germany (2)
- Goethe, Johann Wolfgang von (2)
- HCMV (2)
- HIV (2)
- Heavy-ion collisions (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Machine learning (2)
- Magnetic resonance imaging (2)
- Osteoporosis (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Primary care (2)
- Psychiatric disorders (2)
- QCD (2)
- Quarkonium (2)
- RCT (2)
- Rare diseases (2)
- Relativistic heavy-ion collisions (2)
- SARS-CoV-2 (2)
- Shear viscosity (2)
- Single electrons (2)
- Spine (2)
- Targeted therapy (2)
- Tomography (x-ray computed) (2)
- Vormärz (2)
- chemotherapy (2)
- kidney (2)
- lifestyle intervention (2)
- lockdown (2)
- low-glycaemic meal replacement (2)
- magnetic resonance imaging (2)
- mortality (2)
- multicentre study (2)
- nutlin-3 (2)
- oncomodulation (2)
- p53 (2)
- penile cancer (2)
- protein-rich (2)
- squamous cell carcinoma (2)
- survival (2)
- targeted therapy (2)
- weight reduction (2)
- 900 GeV (1)
- ACLF (1)
- ADHD (1)
- AKT (1)
- ALICE detector (1)
- ASCT (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Adhesion (1)
- Advanced stage (1)
- Age determination by skeleton (1)
- Aging (1)
- Agoraphobia (1)
- Agreement (1)
- All-trans retinoic acid (1)
- Anemia (1)
- Angiogenesis (1)
- Angiography (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Antifungal agents (1)
- Apheresis (1)
- Artificial Intelligence (1)
- Aspergillosis (1)
- Assessment of care (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- B cell malignancies (1)
- B-slope (1)
- Beam loss (1)
- Biodiversity Data (1)
- Biografie (1)
- Biomonitoring (1)
- Blood (1)
- Bloodstream infections (1)
- Bodensee (1)
- Bodensee-Gebiet (1)
- Bone diseases, Metabolic (1)
- Bone marrow (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Brain (1)
- Brain tumor (1)
- Brief (1)
- Burden of disease (1)
- CHIP (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COVID (1)
- CRPC (1)
- CT dual-energy computed tomography (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CXCR4 (1)
- Calcium (1)
- Cancer (1)
- Cancer Staging (1)
- Cancer genomics (1)
- Cementation (1)
- Central Europe (1)
- Centrality Class (1)
- Centrality Selection (1)
- Ceramic (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Checkpoint inhibitor (1)
- Chemotherapy (1)
- Chronic care model (1)
- Chronic diseases (1)
- Chronic medical conditions (1)
- Circular accelerators (1)
- Cleanliness level (1)
- Clinical Trials and Observations (1)
- Clinical genetics (1)
- Clinical trial (1)
- Clinical variation (1)
- Coalescence (1)
- Cognitive training (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Colon capsule endoscopy (1)
- Comparative analysis (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Complicated stage (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computed tomography, X-ray (1)
- Congenital ocular motor apraxia (1)
- Conservation (1)
- Contrast agent (1)
- Coping (1)
- Course (1)
- Critical point (1)
- Data sharing (1)
- Deep neural network (1)
- Deuteron production (1)
- Deutsch (1)
- Devic disease (1)
- Devic syndrome (1)
- Di-hadron correlations (1)
- Diagnosis (1)
- Diagnostic imaging (1)
- Diagnostics (1)
- Digitization (1)
- Direct reactions (1)
- Disease Activity (1)
- Dual-Source CT (1)
- Dual-energy computed tomography (1)
- EGFR (1)
- Early Rheumatoid Arthritis (1)
- Ecotoxicology (1)
- Edema (1)
- Elderly (1)
- Elderly patients (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Ellenberg indicator values (1)
- Emotions (1)
- Environmental Chemistry (1)
- Epilepsy (1)
- Everolimus (1)
- Evidence-based guidelines (1)
- Family practice (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- First-line regimen (1)
- Frailty (1)
- Frieden (1)
- Friedenskonferenz (1)
- Functionally-impaired elderly (1)
- G-CSF (1)
- G207 (1)
- Gene regulation (1)
- General practice (1)
- General practitioners (1)
- Genetics (1)
- Glioma (1)
- Gradient boosting (1)
- Gram negative bacteria (1)
- Groomed jet radius (1)
- H1N1 (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HIV-1 Genotypisierung (1)
- HIV-1 genotyping (1)
- HL7 FHIR (1)
- HSCT (1)
- HSV-1 (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hafis (1)
- Hard Scattering (1)
- Health-related quality of life (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Hemagglutination inhibition assay (1)
- Hematologic malignancies (1)
- Hematopoietic stem cell transplant (1)
- Hematopoietic stem cell transplantation (1)
- Herbaria (1)
- Herniated disk (1)
- High-dose chemotherapy (1)
- Higher moments (1)
- Hypertension (1)
- Image processing (1)
- Image processing (computer-assisted) (1)
- Imaging genetics (1)
- In-TIPS thrombosis (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Intensity interferometry (1)
- Intensive care units (1)
- Interference fragmentation function (1)
- Intervertebral disc displacement (1)
- Interview (1)
- Invariant Mass Distribution (1)
- Invasive candidiasis (1)
- Ionisation energy loss (1)
- J.W. Goethe (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- Joubert syndrome (1)
- Jugend <Motiv> (1)
- Konstanz (1)
- LEOSS (1)
- Landkreis Konstanz (1)
- Lenalidomide (1)
- Long-term follow-up (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Lung Cancer (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- MDM2 (1)
- MSC (1)
- MSC2013 (1)
- MYC (1)
- Material budget (1)
- Mental health and psychiatry (1)
- Mid-rapidity (1)
- Minimal invasive (1)
- Minimum Bias (1)
- Mobilization (1)
- Molar tooth sign (1)
- Molecular biology (1)
- Molecular matched therapy (1)
- Molecular profiling (1)
- Molecular subtypes (1)
- Monolithic crown (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-syndrome classification (1)
- Multi-wire proportional drift chamber (1)
- Multidetector Computed Tomography (1)
- Multidetector computed tomography (1)
- Multimorbid patients (1)
- Multiple myeloma (1)
- Multiple parton interactions (1)
- Multivariate analysis (1)
- Mycoses (1)
- Myeloid Neoplasia (1)
- München (1)
- N-myc (1)
- NAFL (1)
- NASH (1)
- NCAM (1)
- NMO-IgG (1)
- NOTCH (1)
- NPSR1 (1)
- NSAIDs (1)
- NSCLC (1)
- Neoplasms (1)
- Neural network (1)
- Neurodegenerative syndromes (1)
- Neuromyelitis optica (1)
- Neuroscience (1)
- Neutropenia (1)
- Non-small cell lung cancer (1)
- Nonfermenter (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- Nucleophosmin-1 (1)
- Oldest-old (1)
- Oncology (1)
- Online Survey (1)
- Oriental literature (1)
- Osteoporotic fractures (1)
- Outcome (1)
- Outcomes research (1)
- PEM-technology (1)
- PYTHIA (1)
- Pain (1)
- Panic disorder (1)
- Particle and Resonance Production (1)
- Patient-centred care (1)
- Patient-reported outcomes (1)
- Pb–Pb (1)
- Phantoms (imaging) (1)
- Pharmacotherapy (1)
- Phospho-soda (1)
- Photon counting (1)
- Physician report (1)
- Physiology (1)
- PillCamColon2 (1)
- Plasmacytoid dendritic cell (1)
- Plasticity (1)
- Plerixafor (1)
- Polyps (1)
- Positron emission tomography (1)
- Predictive model (1)
- Production Cross Section (1)
- Prognosis (1)
- Properties of Hadrons (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Psoriasis vulgaris (1)
- Psychometrics (1)
- QGP (1)
- Qualitative research (1)
- Quality of life (1)
- Quantitative Imaging (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Questionnaires (1)
- RAS-ID-Gramneg (1)
- RHIC (1)
- RITA (1)
- ROS1 (1)
- Radiology (1)
- Radiomics (1)
- Random forest (1)
- Rapidity Range (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Renal cell carcinoma (1)
- Research Infrastructure (1)
- Research funding (1)
- Resistenztestung (1)
- Resolution Parameter (1)
- Retrospective studies (1)
- Retrospective study (1)
- Rezeption (1)
- Rhabdomyoma (1)
- Rheumatoid Arthritis (1)
- Rheumatoid arthritis (1)
- Rheumatology (1)
- Second-line treatment (1)
- Seizure (1)
- Self-assessment (1)
- Self-report (1)
- Semantics (1)
- Sequelae (1)
- Sequence (1)
- Shell model (1)
- Sicherheitskonferenz (1)
- Single muons (1)
- Social support (1)
- Socioeconomic status (1)
- SoftDrop (1)
- Spectroscopic factors & electromagnetic moments (1)
- Spinal fractures (1)
- Splitting function (1)
- Stem cell (1)
- Stenotrophomonas maltophilia (1)
- Support vector machine (1)
- Syntax (1)
- Systematic Uncertainty (1)
- Systemic treatment (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- TBI (1)
- TIPS (1)
- TR (1)
- Taxonomy (1)
- Therapiemonitoring (1)
- Therapy (1)
- Thermal model (1)
- Tierökologie (1)
- Time Projection Chamber (1)
- Tomography (1)
- Toxicity (1)
- Tracking (1)
- Transition radiation detector (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transplantation (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment modification (1)
- Trigger (1)
- TruGene (1)
- Tumor heterogeneity (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- USP28 (1)
- Usability (1)
- Vasculitis (1)
- Vector Boson Production (1)
- ViroSeq (1)
- Virtual noncalcium reconstructions (1)
- Wasservögel (1)
- Westphal-Paradigm (1)
- White-matter microstructure (1)
- X-ray computed (1)
- Xenon-based gas mixture (1)
- Zirconia (1)
- accident (1)
- acute-on-chronic liver failure (1)
- aging (1)
- allocation (1)
- angiography (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- aquaporin-4 (AQP4) antibody (1)
- arthritis (1)
- atypical EGFR mutations (1)
- autologous stem cell transplantation (1)
- biogeographic legaciese (1)
- bioindication (1)
- biomarker (1)
- blood pressure (1)
- bortezomib (1)
- brain metastases (1)
- brain metastasis (1)
- breeding birds (1)
- c-MET (1)
- cART (1)
- cabozantinib (1)
- cancer (1)
- cancer cell malignancy (1)
- cardiac autonomic regulation (1)
- castration resistance (1)
- cell lines (1)
- central nervous system infection (1)
- cerebral pseudoprogression (1)
- cerebrospinal fluid (1)
- chemoresistance (1)
- child (1)
- cirrhosis (1)
- clinical features (1)
- clinical trials (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- computer-assisted (1)
- dE/dx (1)
- data sharing (1)
- dementia (1)
- detector (1)
- diagnosis (1)
- diagnostic imaging (1)
- diffuse large B cell lymphoma (1)
- diffusion tensor imaging (1)
- drug resistance (1)
- dysbiosis (1)
- epidemiology (1)
- eutrophication (1)
- experimental results (1)
- fMRI (1)
- fasting insulin (1)
- forest classification (1)
- forest functional similarity (1)
- formula diet (1)
- fourth (1)
- gene expression profiling (1)
- geriatrics (1)
- global change (1)
- graft (1)
- guideline (1)
- habitat destruction (1)
- harnwegspathogene Enterobacteriacae (1)
- health information interoperability (1)
- healthcare systems (1)
- heart rate (1)
- heavy ion experiments (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- hospital admission (1)
- host response (1)
- human cytomegalovirus (1)
- human rhabdomyosarcoma (1)
- immune checkpoint inhibitors (1)
- immune checkpoint inhibitors (ICI) (1)
- immune related adverse events (irAE) (1)
- immunocompromised patient (1)
- immunotherapy (1)
- in vivo dosimetry (1)
- induction regimen (1)
- inflammation (1)
- injury (1)
- inpatient hospital admissions (1)
- insulin (1)
- integrins (1)
- interstitial lung disease (1)
- land use (1)
- lenalidomide (1)
- leptin (1)
- leukemia (1)
- liver (1)
- long-term infection (1)
- longitudinally extensive transverse myelitis (1)
- loss (1)
- low-carbohydrate (1)
- low-dose imaging (1)
- mTOR (1)
- mTOR inhibitor (1)
- male (1)
- marker (1)
- mechanical ventilation (1)
- medical informatics initiative (1)
- metabolic syndromes (1)
- metastatic prostate cancer (1)
- microbiome (1)
- mild cognitive impairment (1)
- multidetector computed tomography (1)
- multimorbidity (1)
- multiple myeloma (1)
- myositis (1)
- neoadjuvant immunochemotherapy (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological complication (1)
- neurological manifestations (1)
- neurological side effects (1)
- neutralizing antibodies (1)
- nitrogen deposition (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- non-fermenter (1)
- non-small-cell lung cancer (1)
- obesity (1)
- overweight (1)
- p+p collisions (1)
- p53 activator (1)
- p73 (1)
- pandemic (1)
- pediatric intensive care (1)
- pembrolizumab (1)
- phylogenetic community distance (1)
- polypharmacy (1)
- population development (1)
- population size data (1)
- portal vein (1)
- primary care (1)
- prostate carcinoma cells (1)
- pulmonary failure (1)
- pulse wave velocity (1)
- quark gluon plasma (1)
- radiation (1)
- radiation dosage (1)
- radiation dosimetry (1)
- radiation protection (1)
- re-transplantation (1)
- recurrent optic neuritis (1)
- red data list (1)
- renal failure (1)
- repeated (1)
- resistance testing (1)
- resistant cell lines (1)
- respiratory failure (1)
- ribonucleotide reductase (1)
- security conference (1)
- soil nutrients (1)
- somatic mutations (1)
- spectra (1)
- spike protein (1)
- stereotactic radiosurgery (1)
- symbolism (1)
- therapy monitoring (1)
- third (1)
- threat factors (1)
- thrombosis (1)
- tivantinib (1)
- trauma (1)
- treatment (1)
- trials registry (1)
- tropical forests (1)
- tumor dissemination (1)
- university hospitals (1)
- uropathogenic enterobacteriacae (1)
- variants of concern (1)
- vegetation-plot data (1)
- x-ray techniques (1)
- ΔNp63 (1)
- √sN N = 2.76 TeV (1)
Institute
Schriftenschau
(2011)
Background: In oldest-old patients (>80), few trials showed efficacy of treating hypertension and they included mostly the healthiest elderly. The resulting lack of knowledge has led to inconsistent guidelines, mainly based on systolic blood pressure (SBP), cardiovascular disease (CVD) but not on frailty despite the high prevalence in oldest-old. This may lead to variation how General Practitioners (GPs) treat hypertension. Our aim was to investigate treatment variation of GPs in oldest-olds across countries and to identify the role of frailty in that decision.
Methods: Using a survey, we compared treatment decisions in cases of oldest-old varying in SBP, CVD, and frailty. GPs were asked if they would start antihypertensive treatment in each case. In 2016, we invited GPs in Europe, Brazil, Israel, and New Zealand. We compared the percentage of cases that would be treated per countries. A logistic mixed-effects model was used to derive odds ratio (OR) for frailty with 95% confidence intervals (CI), adjusted for SBP, CVD, and GP characteristics (sex, location and prevalence of oldest-old per GP office, and years of experience). The mixed-effects model was used to account for the multiple assessments per GP.
Results: The 29 countries yielded 2543 participating GPs: 52% were female, 51% located in a city, 71% reported a high prevalence of oldest-old in their offices, 38% and had >20 years of experience. Across countries, considerable variation was found in the decision to start antihypertensive treatment in the oldest-old ranging from 34 to 88%. In 24/29 (83%) countries, frailty was associated with GPs’ decision not to start treatment even after adjustment for SBP, CVD, and GP characteristics (OR 0.53, 95%CI 0.48–0.59; ORs per country 0.11–1.78).
Conclusions: Across countries, we found considerable variation in starting antihypertensive medication in oldest-old. The frail oldest-old had an odds ratio of 0.53 of receiving antihypertensive treatment. Future hypertension trials should also include frail patients to acquire evidence on the efficacy of antihypertensive treatment in oldest-old patients with frailty, with the aim to get evidence-based data for clinical decision-making.
Background: Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CSF.
Methods: Healthy male volunteer donors with a documented average mobilization response to G-CSF received, following ≥6 weeks wash-out, a 1–2 h infusion of 500–2500 µg/kg of balixafortide. Safety, tolerability, pharmacokinetics and pharmacodynamics were assessed.
Results: Balixafortide was well tolerated and rated favorably over G-CSF by subjects. At all doses tested balixafortide mobilized HSPC. In the dose range between 1500 and 2500 µg/kg mobilization was similar, reaching 38.2 ± 2.8 CD34 + cells/µL (mean ± SEM). Balixafortide caused mixed leukocytosis in the mid-20 K/µL range. B-lymphocytosis was more pronounced, whereas neutrophilia and monocytosis were markedly less accentuated with balixafortide compared to G-CSF. At the 24 h time point, leukocytes had largely normalized.
Conclusions: Balixafortide is safe, well tolerated, and induces efficient mobilization of HSPCs in healthy male volunteers. Based on experience with current apheresis technology, the observed mobilization at doses ≥1500 µg/kg of balixafortide is predicted to yield in a single apheresis a standard dose of 4× 10E6 CD34+ cells/kg from most individuals donating for an approximately weight-matched recipient. Exploration of alternative dosing regimens may provide even higher mobilization responses.
Trial Registration European Medicines Agency (EudraCT-Nr. 2011-003316-23) and clinicaltrials.gov (NCT01841476)
Brain metastases are a common finding upon initial diagnosis of otherwise locally limited non-small cell lung cancer. We present a retrospective case series describing three cases of patients with symptomatic, synchronous brain metastases and resectable lung tumors. The patients received local ablative treatment of the brain metastases followed by neoadjuvant immunochemotherapy with pemetrexed, cisplatin, and pembrolizumab. Afterwards, resection of the pulmonary lesion with curative intent was performed. One patient showed progressive disease 12 months after initial diagnosis, and passed away 31 months after initial diagnosis. Two of the patients are still alive and maintain a good quality of life with a progression-free survival and overall survival of 28 and 35 months, respectively, illustrating the potential of novel combinatorial treatment approaches.
Objectives: To investigate the prevalence of depressive symptoms in rheumatoid arthritis (RA) patients using two previously validated questionnaires in a large patient sample, and to evaluate depressive symptoms in the context of clinical characteristics (e.g. remission of disease) and patient-reported impact of disease.
Methods: In this cross-sectional study, the previously validated Patient Health Questionnaire (PHQ-9) and Beck-Depression Inventory II (BDI-II) were used to assess the extent of depressive symptoms in RA patients. Demographic background, RA disease activity score (DAS28), RA impact of disease (RAID) score, comorbidities, anti-rheumatic therapy and antidepressive treatment, were recorded. Cut-off values for depressive symptomatology were PHQ-9 ≥5 or BDI-II ≥14 for mild depressive symptoms or worse and PHQ-9 ≥ 10 or BDI-II ≥ 20 for moderate depressive symptoms or worse. Prevalence of depressive symptomatology was derived by frequency analysis while factors independently associated with depressive symptomatology were investigated by using multiple logistic regression analyses. Ethics committee approval was obtained, and all patients provided written informed consent before participation.
Results: In 1004 RA-patients (75.1% female, mean±SD age: 61.0±12.9 years, mean disease duration: 12.2±9.9 years, DAS28 (ESR): 2.5±1.2), the prevalence of depressive symptoms was 55.4% (mild or worse) and 22.8% (moderate or worse). Characteristics independently associated with depressive symptomatology were: age <60 years (OR = 1.78), RAID score >2 (OR = 10.54) and presence of chronic pain (OR = 3.25). Of patients classified as having depressive symptoms, only 11.7% were receiving anti-depressive therapy.
Conclusions: Mild and moderate depressive symptoms were common in RA patients according to validated tools. In routine clinical practice, screening for depression with corresponding follow-up procedures is as relevant as incorporating these results with patient-reported outcomes (e.g. symptom state), because the mere assessment of clinical disease activity does not sufficiently reflect the prevalence of depressive symptoms.
Clinical trial registration number: This study is registered in the Deutsches Register Klinischer Studien (DRKS00003231) and ClinicalTrials.gov (NCT02485483).
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior. Mechanisms involved in the reduced tumor cell proliferation included a downregulation of MYC and its target genes. Lack of MYC expression was also confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 was upregulated in DEV tumor cells after coculture with T cells or monocytes and its expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new insights into the pathogenesis of LP-DLBCL and an explanation for the relatively low tumor cell content. Moreover, the findings suggest that treatment of these patients with immune checkpoint inhibitors may enhance an already ongoing host response in these patients.
Background: To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies for mHSPC.
Material and Methods: Of 213 mHSPC patients diagnosed between 01/2013-12/2020 who subsequently developed metastatic castration resistant prostate cancer (mCRPC), 204 eligible patients were analyzed after having applied exclusion criteria. mHSPC patients were classified into TTCR <12, 12-18, 18-24, and >24 months and analyzed regarding OS. Moreover, further OS analyses were performed after having developed mCRPC status according to TTCR. Logistic regression models predicted the value of TTCR on OS.
Results: Median follow-up was 34 months. Among 204 mHSPC patients, 41.2% harbored TTCR <12 months, 18.1% for 12-18 months, 15.2% for 18-24 months, and 25.5% for >24 months. Median age was 67 years and median PSA at prostate cancer diagnosis was 61 ng/ml. No differences in patient characteristics were observed (all p>0.05). According to OS, TTCR <12 months patients had the worst OS, followed by TTCR 12-18 months, 18-24 months, and >24 months, in that order (p<0.001). After multivariable adjustment, a 4.07-, 3.31-, and 6.40-fold higher mortality was observed for TTCR 18-24 months, 12-18 months, and <12 months patients, relative to TTCR >24 months (all p<0.05). Conversely, OS after development of mCRPC was not influenced by TTCR stratification (all p>0.05).
Conclusion: Patients with TTCR <12 months are at the highest OS disadvantage in mHSPC. This OS disadvantage persisted even after multivariable adjustment. Interestingly, TTCR stratified analyses did not influence OS in mCRPC patients.
The human immunodeficiency virus (HIV) protease inhibitor saquinavir shows anticancer activity. Although its nitric oxide-modified derivative saquinavir-NO (saq-NO) was less toxic to normal cells, it exerted stronger inhibition of B16 melanoma growth in syngeneic C57BL/6 mice than saquinavir did. Saq-NO has been shown to block proliferation, upregulate p53 expression, and promote differentiation of C6 glioma and B16 cells. The anticancer activity of substances is frequently hampered by cancer cell chemoresistance mechanisms. Therefore, we here investigated the roles of p53 and the ATP-binding cassette (ABC) transporters P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1) in cancer cell sensitivity to saq-NO to get more information about the potential of saq-NO as anticancer drug. Saq-NO exerted anticancer effects in lower concentrations than saquinavir in a panel of human cancer cell lines. Neither p53 mutation or depletion nor expression of P-gp, MRP1, or BCRP1 affected anticancer activity of saq-NO or saquinavir. Moreover, saq-NO sensitized P-gp-, MRP1-, or BCRP1-expressing cancer cells to chemotherapy. Saq-NO induced enhanced sensitization of P-gp- or MRP1-expressing cancer cells to chemotherapy compared with saquinavir, whereas both substances similarly sensitized BCRP1-expressing cells. Washout kinetics and ABC transporter ATPase activities demonstrated that saq-NO is a substrate of P-gp as well as of MRP1. These data support the further investigation of saq-NO as an anticancer drug, especially in multidrug-resistant tumors.
TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives.
Liveblog München, 2. Februar
(2013)